Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies

Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies is organized by i3 Health.

Dates: October 1, 2021 - September 30, 2022

Description:
Tumor lysis syndrome, which is a potentially life-threatening and rare oncologic emergency, is usually associated with chemotherapy-induced tumor cell death. In this case, potassium, phosphate, as well as nucleic acid, are released into the bloodstream. The release of intracellular material can cause severe metabolic abnormalities, such as hyperuricemia or hyperphosphatemia. This may lead to acute renal injury and hypokalemia, hypocalcemia, and neuromuscular symptoms. TLS can prevent or delay treatment with potentially lifesaving chemotherapy (Dinnel and al., 2015). TLS can also cause kidney damage, heart disease, fluid retention, and neuromuscular, and gastrointestinal symptoms. This may result in a reduction in chemotherapy dosing or alteration of the choice of cytotoxic agents (McBride & Westervelt 2012). Prevention is the best management strategy. However, about 3% to 5% are at risk for chemotherapy (Baudon, et al., 2016). TLS patients have a 15% mortality rate (Jones and al. 2015).
Learning Objectives -
Participants should be able:
• Evaluate the potential for TLS in relation to emerging treatments for hematologic malignancies
• Create evidence-based management strategies to maximize the prevention, detection, and treatment for TLS in patients suffering from hematologic malignancies
• Use monitoring strategies to monitor the uric acid levels of patients with TLS

Note: The learning objectives listed above apply to pharmacists, nurse practitioners, and registered nurses in addition to physicians.

Faculty:
Matthew S. Davids, MD, MMSc
Director of Clinical Research
Dana-Farber Cancer Institute

Amy Goodrich, RN, BSN, MSN, CRNP-AC
Nurse Practitioner
Johns Hopkins Kimmel Cancer Center

Evaluate the most effective techniques for treating tumor lysis syndrome brought on by novel cancer treatments. In this activity, Amy Goodrich, RN, BSN, MSN, CRNP-AC, Nurse Practitioner at Johns Hopkins Kimmel Cancer Center, and Matthew S. Davids, MD, MMSc, Director of Clinical Research at Dana-Farber Cancer Institute, will review plans to optimize prevention, recognition, and treatment as well as talk about emerging therapies and patient monitoring strategies. Take action right away!